الفهرس 
EpilepsyOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
Epilepsy is a common neurological disorder in children and can have a major impact on a child’s development. Epilepsy starts in childhood in 60% of cases and most of the clinically significant aspects of the disease occur during childhood. For decades, the care of epilepsy patients has been limited by a paucity of biomarkers ,so there has been an urgent need to develop biomarkers that can predict the progression of epilepsy and treatment response. Recent advances suggest the possible identification of circulating epilepsy biomarkers - accessible in blood, cerebrospinal fluid or urine.The serum amyloid A (SAA) family comprises a number of differentially expressed apolipoproteins, acute-phase SAA (A-SAA) and constitutive SAA (C-SAA), which are synthesized in response to cytokines and secreted in the acute phase of inflammation. A-SAA is a major acute-phase reactants, and is used as objective biochemical indices of disease activity in a number of different inflammatory processes.
The induction of SAA1 and SAA2 is largely triggered by elevated levels of proinflammatory cytokines, tumor necrosis factor α and interleukin-1, 6 in the circulation.Serum amyloid A (SAA) is an acute phase first class protein discovered a quarter of the century ago. Its concentration depends on clinical findings of the patient, illness activity and the therapy applied and increases in plasma up to 1000-fold within 24 to 48 h after trauma, inflammation or infection.
This study was conducted to evaluate the serum level changes of serum amyloid A protein in the healthy and epileptic children after first episode and after two months of treatment.
Thirty children after first episode of epilepsy were included in our study. All participants in this study were subjected to:a-Full medical history with paying attention to history of first episode of seizure. Seizures and epileptic syndromes were determined according to the guidelines of the International League Against Epilepsy.b-Full clinical examination with paying attention to detailed neurological examination.